Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Neuroscience

Volumn 194, Issue , 2011, Pages 189-194

  Kidd, S K ^a   Schneider, J S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Dopamine; HDAC inhibitor; Neuroprotection; Valproate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; HISTONE DEACETYLASE INHIBITOR; PLACEBO; VALPROIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE DEPLETION; CELL DEATH; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; EXCITOTOXICITY; HISTONE ACETYLATION; HUNTINGTON CHOREA; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TREATMENT DURATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; HISTONE DEACETYLASE INHIBITORS; MALE; MICE; MICE, INBRED STRAINS; NEURAL PATHWAYS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; VALPROIC ACID;

EID: 80053105675     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.010     Document Type: Article

References (43)

1. Anderson D.W., Bradbury K.A., Schneider J.S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 2006, 24:3174-3182.
2. Anderson D.W., Bradbury K.A., Schneider J.S. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced pParkinsonism. Eur J Neurosci 2008, 28:610-617.
3. Aubin N., Curet O., Deffois A., Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998, 71:1635-1642.
4. Bowden C.L., McElroy S.L. History of the development of valproate for treatment of bipolar disorder. J Clin Psychiatry 1995, 56(Suppl 3):3-5.
5. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18:1162-1164.
6. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006, 11:1116-1125.
7. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
8. Chen Y.Y., Chen G., Fan Z., Luo J., Ke Z.J. GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK--N-MC neuroblastoma cells. Biochem Pharmacol 2008, 76:128-138.
9. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 2001, 98:14669-14674.
10. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., Moroni F., Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006, 70:1876-1884.
11. Ferger B., Teismann P., Earl C.D., Kuschinsky K., Oertel W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:256-261.
12. Fisar Z., Hroudová J., Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010, 31:645-656.
13. Fuxe K., Janson A.M., Rosén L., Finnman U.B., Tanganelli S., Morari M., Goldstein M., Agnati L.F. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 1992, 88:117-130.
14. Gurvich N., Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002, 96:45-66.
15. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991:214-228.
16. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):S26-S36. discussion S36-S28.
17. Jenner P., Zeng B.Y., Smith L.A., Pearce R.K., Tel B., Chancharme L., Moachon G. Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset. Exp Brain Res 2000, 133:178-188.
18. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., Arent C.O., Dal-Pizzol F., Quevedo J. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 2011, 45:162-168.
19. +-mediated toxicity by histone deacetylase inhibition. Brain Res 2010, 1354:172-178.
20. Kim H.J., Rowe M., Ren M., Hong J.-S., Chen P.-S., Chuang D.-M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007, 321:892-901.
21. Kuriyama T., Taguchi J., Kuriyama K. Functional alterations in striatal cholinergic and striato-nigral gabaergic neurons following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. Neurochem Int 1990, 16:319-329.
22. Lagrue E., Chalon S., Bodard S., Saliba E., Gressens P., Castelnau P. Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatr Res 2007, 62:14-19.
23. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 1996, 47:S153-S160.
24. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008, 28:2576-2588.
25. Leng Y., Marinova Z., Reis-Fernandes M.A., Nau H., Chuang D.M. Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett 2010, 476:127-132.
26. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989, 501:198-203.
27. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999, 58:31-59.
28. Lv L., Sun Y., Han X., Xu C.C., Tang Y.P., Dong Q. Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition. Brain Res 2011, 1396:60-68.
29. Marinova Z., Ren M., Wendland J.R., Leng Y., Liang M.H., Yasuda S., Leeds P., Chuang D.M. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009, 111:976-987.
30. Melamed E., Martinovits G., Pikarsky E., Rosenthal J., Uzzan A. Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. Eur J Pharmacol 1986, 128:255-257.
31. Mohanakumar K.P., Muralikrishnan D., Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 2000, 864:281-290.
32. Peng G.S., Li G., Tzeng N.S., Chen P.S., Chuang D.M., Hsu Y.D., Yang S., Hong J.S. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 2005, 134:162-169.
33. Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006, 22:40-49.
34. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
35. Rouaux C., Panteleeva I., René F., Gonzalez de Aguilar J.L., Echaniz-Laguna A., Dupuis L., Menger Y., Boutillier A.L., Loeffler J.P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007, 27:5535-5545.
36. Ryu H., Lee J., Olofsson B.A., Mwidau A., Dedeoglu A., Escudero M., Flemington E., Azizkhan-Clifford J., Ferrante R.J., Ratan R.R. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A 2003, 100:4281-4286.
37. Shen H.Y., He J.C., Wang Y., Huang Q.Y., Chen J.F. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 2005, 280:39962-39969.
38. Singer T.P., Castagnoli N., Ramsay R.R., Trevor A.J. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987, 49:1-8.
39. Speciale S.G. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol Teratol 2002, 24:607-620.
40. Suuronen T., Huuskonen J., Pihlaja R., Kyrylenko S., Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003, 87:407-416.
41. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
42. Wang W., Yang Y., Ying C., Li W., Ruan H., Zhu X., You Y., Han Y., Chen R., Wang Y., Li M. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007, 52:1678-1684.
43. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.